GLUE Competitors & Alternatives
Compare Monte Rosa Therapeutics Inc with similar stocks in the same industry
Biotechnology
GLUE
Main Stock$14.07
Tradestie Score
65
Market Cap
$463.20M
Revenue Growth
-0.6%
Analyst Upside
+102.6%
Top Competitors
234 stocks in Biotechnology| Company | Price | Market Cap | P/E | Score | Action |
|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings, Inc. Common Stock
|
$7.45
|
$1.29B | - | 47 | Compare |
|
STOK
Stoke Therapeutics, Inc. Common Stock
|
$29.03
|
$1.29B | - | 57 | Compare |
|
ARDX
Ardelyx, Inc.
|
$3.58
|
$1.29B | - | 40 | Compare |
|
ZYME
Zymeworks Inc.
|
$26.24
|
$1.28B | - | 37 | Compare |
|
NUVB
Nuvation Bio Inc.
|
$6.07
|
$1.27B | - | 40 | Compare |
|
CVAC
CureVac N.V. Ordinary Shares
|
$4.66
|
$1.22B | 7.0 | 54 | Compare |
|
ATAI
ATAI Life Sciences N.V. Common Shares
|
$7.35
|
$1.22B | - | 44 | Compare |
|
PGEN
Precigen, Inc. Common Stock
|
$6.85
|
$1.18B | - | 42 | Compare |
|
ELVN
Enliven Therapeutics, Inc. Common Stock
|
$54.32
|
$1.17B | - | 48 | Compare |
|
INVA
Innoviva, Inc. Common Stock
|
$20.66
|
$1.15B | 4.9 | 44 | Compare |
More GLUE Analysis
Data updated: Sep 12, 2026 | Industry: Biotechnology (SIC 2836)
234 stocks in this industry